Depression subtypes in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 5, 2014, Pages 574-581

  Szigethy, Eva M ^b   Youk, Ada O ^c   Benhayon, David ^b   Fairclough, Diane L ^d   Newara, Melissa C ^b   Kirshner, Margaret A ^b   Bujoreanu, Simona I ^e   Mrakotsky, Christine ^e   Bousvaros, Athos ^e   Srinath, Arvind I ^a   Keljo, David J ^a   Kupfer, David J ^b   Demaso, David R ^e  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Food Science and Human Nutrition   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

comorbid psychiatric and physical illness; depression; inflammatory bowel disease; latent profile analysis; pediatric

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ANHEDONIA; ANOREXIA NERVOSA; ANXIETY; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDREN DEPRESSION RATING SCALE REVISED; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COGNITION; COMORBIDITY; CONDUCT DISORDER; CROHN DISEASE; DEMOGRAPHY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSTHYMIA; ETHNICITY; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MOTOR ACTIVITY; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PANIC; PERCEPTION; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SEPARATION ANXIETY; SOMATIZATION; STEROID THERAPY; STOMA; SYSTEMIC THERAPY; ADOLESCENT; CLASSIFICATION; INFLAMMATORY BOWEL DISEASES; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANXIETY; CHILD; DEPRESSION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84900386954     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000262     Document Type: Article

References (67)

1. Lamers F, Burstein M, He JP, et al. Structure of major depressive disorder in adolescents and adults in the US general population. Br J Psychiatry 2012;201:143-50.
2. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005; 90:2522-30.
3. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
4. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-86.
5. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
6. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.
7. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin 2006; 24:507-19.
8. Jacobson CM, Rosenfeld B, Pessin H, et al. Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 2008;49:64-6.
9. Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008;26:4820-7.
10. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-7.
11. Miller GE, Freedland KE, Duntley S, et al. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005;95:317-21.
12. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-52.
13. Capuron L, Hauser P, Hinze-Selch D, et al. Treatment of cytokine-induced depression. Brain Behav Immun 2002;16:575-80.
14. Lotrich FE, El-Gabalawy H, Guenther LC, et al. The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol Suppl 2011;88:48-54.
15. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25 (1 suppl 1): 39-47.
16. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-6.
17. Lotrich F. Depression symptoms, low-grade inflammatory activity, and new targets for clinical intervention. Biol Psychiatry 2011; 70:111-2.
18. Miller GE, Cole SW. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 2012;72:34-40.
19. Hood KK, Lawrence JM, Anderson A, et al. Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care 2012;35:2443-6.
20. Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol 2010;35:857-69.
21. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr 2004;39:395-403.
22. Regueiro MD, Swoger JM. Clinical Challenges and Complications of IBD. Thorofare, NJ: SLACK Inc; 2013.
23. Thompson RD, Delaney P, Flores I, et al. Cognitive-behavioral therapy for children with comorbid physical illness. Child Adolesc Psychiatr Clin N Am 2011;20:329-48.
24. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999;40:57-87.
25. Ferdinand RF, de Nijs PF, van Lier P, et al. Latent class analysis of anxiety and depressive symptoms in referred adolescents. J Affect Disord 2005;88:299-306.
26. Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry 1996;53:1129-36.
27. McLafferty L, Craig A, Levine A, et al. Thematic analysis of physical illness perceptions in depressed youth with inflammatory bowel disease. Inflamm Bowel Dis 2011;17 (suppl 1):S54.
28. Kovacs M. Children's Depression Inventory (CDI) Manual. New York: Multi-Health Systems; 1992.
29. Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and sub-syndromal depression. J Am Acad Child Adolesc Psychiatry 2007; 46:1290-8.
30. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8.
31. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
32. Gonzalez-Tejera G, Canino G, Ramirez R, et al. Examining minor and major depression in adolescents. J Child Psychol Psychiatry 2005; 46:888-99.
33. Engstrom I. Mental health and psychological functioning in children and adolescents with inflammatory bowel disease: a comparison with children having other chronic illnesses and with healthy children. J Child Psychol Psychiatry 1992;33:563-82.
34. Poznanski EO, Mokros HB. Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles: Western Psychological Services; 1996.
35. Poznanski EO, Grossman JA, Buchsbaum Y, et al. Preliminary studies of the reliability and validity of the children's depression rating scale. J Am Acad Child Psychiatry 1984;23:191-7.
36. Birmaher B, Khetarpal S, Brent D, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997;36:545-53.
37. Pavuluri M, Birmaher B. A practical guide to using ratings of depression and anxiety in child psychiatric practice. Curr Psychiatry Rep 2004; 6:108-16.
38. Birmaher B, Brent DA, Chiappetta L, et al. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry 1999;38:1230-6.
39. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557-63.
40. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
41. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
42. Walker LS, Smith CA, Garber J, et al. Development and validation of the Pain Response Inventory for children. Psychol Assess 1997;9:392-405.
43. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J Psychosom Res 2006;60:631-7.
44. Nakao K, Treas J. The 1989 Socioeconomic Index of Occupations: Construction from the 1989 Occupational Prestige Scores (General Social Survey Methodological Report no. 74). Chicago, IL: University of Chicago; 1992.
45. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-60.
46. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102.
47. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
48. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', im-munotherapy and antidepressive treatment. Int J Neuropsychopharmacol 2002;5:389-99.
49. Hauser W, Schmidt C, Stallmach A. Depression and mucosal pro-inflammatory cytokines are associated in patients with ulcerative colitis and pouchitis-a pilot study. J Crohns Colitis 2011;5:350-3.
50. Szigethy E, McLafferty L, Goyal A. Inflammatory bowel disease. Pediatr Clin North Am 2011;58:903-20.
51. Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn's disease in the elderly: a comparison with young adults. J Clin Gastroenterol 1998;27:129-33.
52. Andersson P, Olaison G, Hallbook O, et al. Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis Colon Rectum 2003;46:1685-9.
53. Farrokhyar F, Marshall J, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38-46.
54. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004;49:469-74.
55. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31-41.
56. Bennett DS, Ambrosini PJ, Kudes D, et al. Gender differences in adolescent depression: do symptoms differ for boys and girls? J Affect Disord 2005;89:35-44.
57. Danese A, Moffitt TE, Harrington H, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med 2009;163:1135-43.
58. Mrakotsky C, Forbes PW, Bernstein JH, et al. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. J Int Neuropsychol Soc 2013;19:96-109.
59. Suvak B, Beyazit Y, Sayilir A, et al. Effects of corticosteroid therapy on depression and inflammation in ulcerative colitis patients. J Crohns Colitis 2011;5:375-6.
60. Fardet L, Kassar A, Cabane J, et al. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Safety 2007;30:861-81.
61. Jelsness-Jorgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease. World J Gastroenterol 2012;18:445-52.
62. Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012;18: 2301-9.
63. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008;103:1989-97.
64. Szigethy E, Craig AE, Iobst EA, et al. Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. Inflamm Bowel Dis 2009;15:69-74.
65. Rao U, Chen LA. Characteristics, correlates, and outcomes of childhood and adolescent depressive disorders. Dialogues Clin Neurosci 2009; 11:45-62.
66. Shelton RC, Miller AH. Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 2010;91:275-99.
67. Paykel ES, Parker RR, Rowan PR, et al. Nosology of atypical depression. Psychol Med 1983;13:131-9.